Nakashima Shinji, Morikawa Masayuki, Komatsu Kanshi, Matsuura Akihiro, Sato Noriyuki, Abe Tomio
Department of Thoracic and Cardiovascular Surgery, Sapporo, Japan.
J Heart Lung Transplant. 2005 Apr;24(4):462-9. doi: 10.1016/j.healun.2004.02.011.
NKH477 was recently identified as a water-soluble forskolin derivative and was reported to prolong survival of murine cardiac allografts. However, the mechanism of the efficacy is not clear in vivo. The aim of this study was to investigate the immunosuppressive effects of NKH477 on acute lung allograft rejection in the rat model and its mechanism of action in vivo.
Left lungs were transplanted orthotopically from Brown-Norway donors to Lewis recipients. Recipient rats were untreated or treated daily with different doses of NKH477. Grafts were excised on Day 3 or Day 5 to determine histopathological rejection and expressions of interleukin (IL)-2, IL-4, IL-10, and interferon (IFN)-gamma by enzyme-linked immunosorbent assay. The cytokine expression at Day 3 or Day 5 was also evaluated in recipient spleens by immunohistochemistry. Furthermore, mesenteric lymph node cells from recipients at Day 5 were cultured alone or stimulated with donor antigens for 72 hours to determine cell proliferation by means of thymidine incorporation.
NKH477 significantly extended allograft survival time in a dose-dependent manner and reduced histopathological rejection. Treatment with NKH477 inhibited IFN-gamma and IL-10 expression, whereas expression of these cytokines were markedly upregulated in the untreated allografts. Expression of IL-2 and IL-10 also increased in the spleen of untreated allorecipients. NKH477 suppressed expression of both cytokines in the spleen. In addition, lymphocyte proliferation was inhibited in NKH477-treated recipients as compared with untreated recipients.
These results suggest that NKH477 exerts an antiproliferative effect on lymphocytes in vivo with an altered cytokine profile in rat recipients of lung allografts.
NKH477最近被鉴定为一种水溶性福司可林衍生物,据报道它能延长小鼠心脏同种异体移植的存活时间。然而,其体内疗效机制尚不清楚。本研究旨在探讨NKH477对大鼠模型急性肺同种异体移植排斥反应的免疫抑制作用及其体内作用机制。
将左肺从布朗-挪威供体原位移植到刘易斯受体。受体大鼠不接受治疗或每天用不同剂量的NKH477治疗。在第3天或第5天切除移植物,通过酶联免疫吸附测定法确定组织病理学排斥反应以及白细胞介素(IL)-2、IL-4、IL-10和干扰素(IFN)-γ的表达。还通过免疫组织化学评估第3天或第5天受体脾脏中的细胞因子表达。此外,将第5天受体的肠系膜淋巴结细胞单独培养或用供体抗原刺激72小时,通过胸腺嘧啶核苷掺入法确定细胞增殖。
NKH477以剂量依赖性方式显著延长同种异体移植存活时间,并减轻组织病理学排斥反应。NKH477治疗抑制了IFN-γ和IL-10的表达,而在未治疗的同种异体移植中这些细胞因子的表达明显上调。未治疗的同种异体受体脾脏中IL-2和IL-10的表达也增加。NKH477抑制了脾脏中这两种细胞因子的表达。此外,与未治疗的受体相比,NKH477治疗的受体中淋巴细胞增殖受到抑制。
这些结果表明,NKH477在体内对淋巴细胞具有抗增殖作用,且在肺同种异体移植大鼠受体中细胞因子谱发生改变。